Pediatric Infection and Vaccine

  • 제17권2호
  • /
  • Pages.156-168
  • /
  • 2010
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

한국의 건강한 영아를 대상으로 DTPa-IPV 혼합백신을 접종한 경우와 DTPa 백신과 IPV 백신을 각각 투여하였을 경우의 면역원성, 반응원성 및 안전성

Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants

  • 김창휘 (순천향대학교 부천병원 소아청소년과) ;
  • 차성호 (경희대학교병원 소아청소년과) ;
  • 신손문 (제일병원 소아청소년과) ;
  • 김천수 (계명대학교 동산의료원 소아청소년과) ;
  • 최영륜 (전남대학교병원 소아청소년과) ;
  • 홍영진 (인하대병원소아청소년과) ;
  • 최명재 (인제대학교 상계백병원 소아청소년과) ;
  • 김광남 (한림대학교 한강성심병원 소아청소년과) ;
  • 허재균 (가톨릭대학교 성바오로병원 소아청소년과) ;
  • 조대선 (전북대학교병원 소아청소년과) ;
  • 김성신 (순천향대학교 부천병원 소아청소년과) ;
  • 이상락 (계명대학교 동산의료원 소아청소년과) ;
  • 송은송 (전남대학교병원 소아청소년과) ;
  • ;
  • 옥진주 ;
  • ;
  • ;
  • 김정수 (전북대학교병원 소아청소년과)
  • Kim, Chang Hwi (Department of Pediatrics, Soonchunhyang University Bucheon Hospital) ;
  • Cha, Sung Ho (Department of Pediatrics, Kyunghee University Hospital) ;
  • Shin, Son Moon (Department of Pediatrics, Cheil General Hospital and Women's Healthcare Center Kwandong University College of Medicine) ;
  • Kim, Chun Soo (Department of Pediatrics, Keimyung Dongsan Medical Center Keimyung University) ;
  • Choi, Young Youn (Department of Pediatrics, Chonnam National University Hospital) ;
  • Hong, Young Jin (Department of Pediatrics, Inha University Hospital) ;
  • Chey, Myoung Jae (Department of Pediatrics, Sanggye Paik Hospital) ;
  • Kim, Kwang Nam (Department of Pediatrics, Hangang Sacred Heart Hospital) ;
  • Hur, Jae Kyun (Department of Pediatrics, St. Paul's Hospital) ;
  • Jo, Dae Sun (Department of Pediatrics, Chonbuk National University Hospital) ;
  • Kim, Sung Shin (Department of Pediatrics, Soonchunhyang University Bucheon Hospital) ;
  • Lee, Sang Lak (Department of Pediatrics, Keimyung Dongsan Medical Center Keimyung University) ;
  • Song, Eun Song (Department of Pediatrics, Chonnam National University Hospital) ;
  • Ramakrishnan, Gunasekaran (GlaxoSmithKline Biologicals) ;
  • Ok, Jin Ju (GlaxoSmithKline Biologicals) ;
  • Van Der Meeren, Olivier (GlaxoSmithKline Biologicals) ;
  • Bock, Hans L. (GlaxoSmithKline Biologicals) ;
  • Kim, Jung Soo (Department of Pediatrics, Chonnam National University Hospital)
  • 투고 : 2010.06.10
  • 심사 : 2010.11.03
  • 발행 : 2010.12.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적 : 디프테리아, 파상풍, 백일해 및 불활화 폴리오 백신인 GlaxoSmithKline Biologicals의 $Infanrix^{TM}$-IPV(DTPa-IPV)를 접종시, 시판되고 있는 DTPa 백신과 IPV 백신을 각각 다른 부위에 동시 접종 했을 때(DTPa+IPV)와의 면역원성과 반응원성을 비교하기 위하여 본 연구를 시행하였다. 방법 : 생후 8-12주의 영아 458명을 무작위 배정하여, 각각 2, 4, 6개월에 DTPa-IPV 혹은 DTPa+IPV를 3회 기초접종 하였다. 면역반응을 확인하기 위하여 백신접종 전과 후에 채혈을 하였다. 반응원성은 각 백신 접종 후 작성된 증상기록카드를 통하여 평가하였다. 결과 : 3차 백신접종 한달 후에, 항-디프테리아, 항-파상풍 그리고 항-폴리오바이러스 type 1, 2, 3에 대한 혈청 방어율(seroprotection rate)은 ${\geq}99.5%$였고, 두군 모두 백일해 항원에 대한 백신 반응률(vaccine res-ponse rates)은 적어도 98.6% 이상이었다. 두 군간의 비 열등성은 사전 정의된 통계적 기준에 따라 보여주었다. 국소증상과 전신증상 발생률은 두 군 모두 비슷하게 보고되었고, grade 3의 증상이 DTPa-IPV 투여군에서 4.3%, DTPa+IPV 투여군에서는 4.5%로 보고되었다. 두 건의 중대한 이상반응(모두 발열)이 DTPa-IPV 투여 후에 보고되었고, 백신과의 연관성이 있는 것으로 간주되었다. 두 명의 영아는 모두 회복되었다. 결론 : DTPa-IPV 혼합백신은 한국의 소아들에게 기초접종으로 3회 투여시 충분한 면역반응을 보였고, 내약성이 우수했다. DTPa-IPV는 한국 예방접종 스케줄에 편입되어, 기초 접종을 완료하기 위한 접종 회수를 줄일 수 있다.

Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, $Infanrix^{TM}$ IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-ose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards. Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were ${\geq}99.5%$ and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully. Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization.

키워드

참고문헌

  1. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Immunization Profile - Republic of Korea [Internet]. [updated 10 Aug 2009; cited 2010 Feb 4]. Available from: http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm?C='kor'
  2. The Korean Pediatric Society. DTaP and Td vaccines. In: Lee HJ, editors. Immunization Guideline. 6th edition. Seoul: The Korean Pediatric Society, 2008.
  3. Kang JM, Kim JH, Lee JH, Kim YT, Kim JH, Song YS, et al. The immunogenicity and safety of a three component DTPa in Korean infants. Korean J Pediatr 2007;50:355- 62. https://doi.org/10.3345/kjp.2007.50.4.355
  4. Kim HH, Shin KH, Kim SN, Lee MS, Yoo SH, Kim JY, et al. Investigation on the immunity to pertussis in Korea. J Korean Soc Microbiol 1999;34:583-9.
  5. Shek LP, Khor ES, Tan GH, Low KT, Ong D, Roy J, et al. Comparative study of the reactogenicity of a threecomponent acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants. Southeast Asian J Trop Med Public Health 2003; 34:863-8.
  6. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003;21:2003-14. https://doi.org/10.1016/S0264-410X(02)00770-3
  7. Division of Vaccine Preventable Disease Control and National Immunization Program. Korea Centers for Disease Control and Prevention Monthly Newsletter 2007;5:28.
  8. Korea Centers for Disease Control and Prevention [Internet]. [cited 2009 Oct 15]. Available from: http://www.cdc.go.kr
  9. Yoo S, Ahn KO, Park EH, Cho HS, Park CY, Lee HR. Epidemiologic and clinical features of pertussis in children (2000.3-2001.3). J Korean Pediatr Soc 2002;45:603-8.
  10. Kim SJ, Kim SH, Jee YM, Kim JS. Vaccine-associated paralytic poliomyelitis: a case report of flaccid monoparesis after oral polio vaccine. J Korean Med Sci 2007; 22:362-4. https://doi.org/10.3346/jkms.2007.22.2.362
  11. World Health Organization (WHO). Major milestone reached in global polio eradication: Western Pacific region is certified polio-free. Press release WHO/71 29 October 2000 [Internet]. Accessed 01-09-2008. Available from: https://www.who.int/inf-pr-2000/en/pr2000-71.html
  12. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care 2007; 13:506-12.
  13. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006;25:507-12. https://doi.org/10.1097/01.inf.0000222413.47344.23
  14. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41. https://doi.org/10.1001/jama.275.1.37
  15. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
  16. Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984;20: 772-4.
  17. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983;11:137-44. https://doi.org/10.1016/S0092-1157(83)80038-9
  18. Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria- tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000;137:304-12. https://doi.org/10.1067/mpd.2000.107796
  19. World Health Organization (WHO). Standard procedure for determining immunity to poliovirus using the microneutralization test. 1993. WHO/EPI/Gen 93
  20. 20) Black S, Friedland LR, Schuind A, Howe B; GlaxoSmith- Kline DTaP-IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 2006;24:6163-71. https://doi.org/10.1016/j.vaccine.2006.04.001
  21. Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008;27:341-6. https://doi.org/10.1097/INF.0b013e3181616180
  22. Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine 2006;24: 6120-8. https://doi.org/10.1016/j.vaccine.2006.05.017
  23. Jacquet JM, Begue P, Grimprel E, Reinert P, Sandbu S, Silfverdal SA, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review. Vaccine 2006;24:2440-8. https://doi.org/10.1016/j.vaccine.2005.12.009
  24. Nilsson L, Faldella G, Jacquet JM, Storsaeter J, Silfverdal SA, Ekholm L. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 2005;37:221-29. https://doi.org/10.1080/00365540410020884
  25. Lin TY, Wang YH, Chang LY, Chui CH, Huang YC, Tang H, et al. Safety and immunogenicity of a diphtheria, tetanus and acellular-pertussis-inactivated poliovirus vaccine/Heamophilus influenza type b combination vaccine administered to Taiwanese infants at 2, 4 and 6 months of age. Chang Gung Med J 2003;26:315-22.
  26. Begue PC, Grimprel EM, Giovannangeli MD, Abitbol VI. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussisinactivated poliovirus vaccine and diphtheria-tetanusinactivated poliovirus vaccine in preadolescents. Pediatr Infect Dis J 1998;17:804-9. https://doi.org/10.1097/00006454-199809000-00011
  27. Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, et al. A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J 2007;26:1057-9. https://doi.org/10.1097/INF.0b013e31813429fa
  28. Immunisation Advisory Centre. Introducing Infanrix$^{\circledR}$- hexa fact sheet for parents and caregivers. Available from: www.immune.org.nz
  29. Weston WM, Klein NP. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. Expert Rev Vaccines 2008;7:1309-20. https://doi.org/10.1586/14760584.7.9.1309